Search Results
Jun 04, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
combination with cemiplimab (PD-1 inhibitor) as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma" "did not each statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy." On
More news about: Pomerantz LLP
Jun 04, 2026, 09:04 ET New Online Training Initiative Equips First Responders to Support Traumatized Children and Families on Crime Scenes
built for law enforcement realities, in close collaboration with the Providence Police Department, a FSRI GO TEAM partner for over 20 years. Providence PD and FSRI are recognized leaders in the co-response model and leveraged a nationwide law enforcement survey with 450 plus respondents spanning 37 states
More news about: Family Service Rhode Island | TIP Center
Jun 03, 2026, 21:52 ET 2026 ASCO LBA | Juncell Therapeutics' GC101 TIL Therapy Achieves Primary Endpoint in the Pivotal Phase II Trial for PD-1 Antibody Failed Advanced Melanoma
Ltd. for PD-1 antibody failed patients with advanced melanoma. Comparing with the control group who received chemotherapy, GC101 TIL therapy demonstrated statistically significant and clinically meaningful efficacy improvement, potentially to benefit patients with advanced melanoma who failed PD-1 antibody[1].
More news about: Juncell Therapeutics
Jun 03, 2026, 15:33 ET EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM
Phase-1b-Studie zu Tarlatamab in Kombination mit YL201, einem B7-H3-gerichteten Antikörper-Wirkstoff-Konjugat, mit oder ohne Anti-Programmed-Death-Ligand-1 (PD-L1) bei Patienten mit ES-SCLC; DeLLphi-311, eine Phase-1b-Studie zu Tarlatamab in Kombination mit Etakafusp alfa (AB248), einem neuartigen, selektiv auf
More news about: Amgen
Jun 03, 2026, 15:16 ET LA COMMISSION EUROPÉENNE APPROUVE IMDYLLTRA® D'AMGEN POUR LE TRAITEMENT DU CANCER DU POUMON À PETITES CELLULES DE STADE ÉTENDU
phase 1b sur le tarlatamab en association avec YL201, un conjugué anticorps médicament ciblant B7-H3, avec ou sans anti-ligand de mort programmée 1 (PD-L1) chez des patients atteints de CPPC-SE ; DeLLphi-311, une étude de phase 1b sur le tarlatamab en association avec l'etakafusp alfa (AB248), une nouvelle
More news about: Amgen
Jun 03, 2026, 14:25 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC
hodnotiacej tarlatamab v kombinácii s YL201 (konjugátom protilátky a liečiva cieleným na B7-H3) s inhibítorom ligandu programovanej bunkovej smrti 1 (PD-L1) alebo bez neho u pacientov s ES-SCLC; štúdie DeLLphi-311 – fázy 1b hodnotiacej tarlatamab v kombinácii s etakafuspom alfa (AB248), novým interleukínom-2
More news about: Amgen
Jun 03, 2026, 13:35 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK IMDYLLTRA® OD SPOLEČNOSTI AMGEN K LÉČBĚ EXTENZIVNÍHO STADIA MALOBUNĚČNÉHO KARCINOMU PLIC
studie tarlatamabu fáze Ib v kombinaci s YL201, konjugátem protilátky a léčiva zaměřeným na B7-H3, s nebo bez inhibice ligandu proteinu programované smrti PD-L1 u pacientů s ES-SCLC; DeLLphi-311, studie tarlatamabu fáze Ib v kombinaci s etakafuspem alfa (AB248), novým interleukinem-2 (IL-2) selektivním pro
More news about: Amgen
Jun 03, 2026, 10:21 ET KOMISJA EUROPEJSA ZATWIERDZA PREPARAT IMDYLLTRA® FIRMY AMGEN DO LECZENIA DROBNOKOMÓRKOWEGO RAKA PŁUCA W POSTACI ROZSIANEJ
ES-SCLC), DeLLphi-310 (badanie fazy I b tarlatamabu w skojarzeniu z YL201 - przeciwciałem sprzężonym z lekiem celującym w B7-H3 - z lub bez inhibitora PD-L1 u pacjentów z ES-SCLC), DeLLphi-311 (badanie fazy I b tarlatamabu w skojarzeniu z etakafusp alfa (AB248), selektywną dla limfocytów T CD8+ interleukiną-2
More news about: Amgen
Jun 03, 2026, 10:00 ET HkeyBio New Platform Launch: AIH, PBC, and IgAN Model Matrix Empowers "One Drug, Multiple Screens" in Autoimmune New Drug R&D
translational value in the development of innovative biologics.In the future, the relevant platforms are expected to support:PK/PD evaluation.Humanized antibody research.Biomarker monitoring.Immunogenicity evaluation.Clinical dose prediction.IND-enabling
More news about: HKeyBio
Jun 03, 2026, 09:43 ET ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN IMDYLLTRA® ДЛЯ ЛЕЧЕНИЯ МЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО НА ЗАПУЩЕННОЙ СТАДИИ
DeLLphi-310, исследование фазы 1b тарлатамаба в комбинации с YL201, конъюгатом антитела, нацеленным на B7-H3, с антипрограммированным лигандом смерти 1 (PD-L1) или без него у пациентов с МРЛ ЗС; DeLLphi-311, исследование фазы 1b тарлатамаба в комбинации с этакафуспом альфа (AB248), новым CD8+ Т-клеточным селективным
More news about: Amgen
Jun 03, 2026, 09:27 ET LA CE APRUEBA IMDYLLTRA® DE AMGEN PARA EL CÁNCER DE PULMÓN DE CÉLULAS PEQUEÑAS EN ESTADIO AVANZADO
fase 1b de tarlatamab en combinación con YL201, un conjugado de anticuerpo-fármaco dirigido a B7-H3, con o sin anti-ligando de muerte programada 1 (PD-L1) en pacientes con ES-SCLC; DeLLphi-311, un estudio de fase 1b de tarlatamab en combinación con etakafusp alfa (AB248), una nueva interleucina-2 (IL-2)
More news about: Amgen
Jun 03, 2026, 08:00 ET Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis
kinexus, Fresenius Medical Care (FME) is advancing connected home dialysis care by bringing together digital modules supporting peritoneal dialysis (PD) and home hemodialysis (HHD) within a single, unified platform. For both therapies, kinexus supports remote therapy monitoring by enabling treatment
More news about: Fresenius Medical Care Holdings, Inc.
Jun 03, 2026, 00:00 ET Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026
commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using
More news about: Antengene Corporation Limited
Jun 02, 2026, 07:30 ET Kazia Therapeutics Appoints James Levine as Chief Financial Officer
licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially
More news about: Kazia Therapeutics Limited
Jun 02, 2026, 07:00 ET Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
The open-label, single-arm Phase 1 study enrolled 11 patients, with advanced solid tumors who had previously progressed following anti-PD-1 immunotherapy and was designed to evaluate the safety and tolerability of BMC128 in combination with Nivolumab. The treatment regimen included a two-week
More news about: Evogene
Jun 01, 2026, 16:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Phase 1b study of tarlatamab in combination with YL201, a B7-H3 targeting antibody drug conjugate, with or without anti-programmed death ligand 1 (PD-L1) in patients with ES-SCLC; DeLLphi-311, a Phase 1b study of tarlatamab in combination with etakafusp alfa (AB248), a novel CD8+ T-cell selective interleukin-2
More news about: Amgen
Jun 01, 2026, 11:00 ET IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
investigator's choice of therapy (ICT) arm reflective of real-world clinical practice that included ipilimumab plus nivolumab (anti-CTLA-4/PD-1) or pembrolizumab (anti-PD-1). The primary endpoint to support accelerated approval is median progression-free survival (PFS) as assessed by blinded independent
More news about: IDEAYA Biosciences, Inc.
Jun 01, 2026, 08:31 ET The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight
is a first-in-class PD-1/VEGF bispecific antibody and the first candidate in this category to advance into Phase III clinical trials. Developed using the company's proprietary Tetrabody platform, the therapy is designed to simultaneously inhibit PD-1 interactions with PD-L1 and PD-L2 while also preventing
More news about: DelveInsight Business Research, LLP
Jun 01, 2026, 08:11 ET Cancer Vaccine Sustains 49 Percent Melanoma Reduction After 5 Years
responses. Immunotherapies like pembrolizumab seek to block checkpoints, specifically the PD-1 protein receptor, making cancer cells more "visible" and vulnerable again to immune cells.Immunotherapies, such as PD-1 inhibitors like pembrolizumab, have become the mainstay for treating melanoma, although
More news about: NYU Langone Health System
Jun 01, 2026, 07:00 ET Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
primarily gynecologic malignancies. Enrolled patients had received a median of five prior therapies, and more than half had previously received anti-PD-1 or PD-L1 therapy.Key Efficacy and Safety findings presented at ASCO included:24% Overall Response Rate (ORR) among
More news about: Citius Oncology, Inc.
Jun 01, 2026, 00:00 ET Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
strategies for MHB088C. Ongoing studies in China include a Phase I/II trial evaluating MHB088C in combination with MHB039A, Minghui's investigational PD-1/VEGF bispecific antibody, in patients with advanced solid tumors, including first-line SCLC expansion cohorts.About Minghui PharmaceuticalMinghui
More news about: Minghui Pharmaceutical
May 31, 2026, 20:15 ET ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
extremely low at only 0.7% (1/139).(2) PD profile demonstrated saturated receptor occupancy and robust T-cell activation/proliferation confirming PD-1/CTLA-4 blockade and deep and sustained VEGFA neutralization.Receptor occupancy (RO) of PD-1/CTLA-4 on peripheral T cells reached
More news about: CStone Pharmaceuticals
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
(all PD-L1 expression levels)—is currently ongoing.About IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein)IBI363 is a first-in-class PD-1/IL-2α-bias bispecific fusion protein developed by Innovent Biologics. It functions by both blocking the PD-1/PD-L1
More news about: Innovent Biologics
May 31, 2026, 20:00 ET D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
efficacy-evaluable patients, an ORR 81.3% was observed across all PD-L1 expression levels, with ORR of 70.6% in patients with PD-L1 TPS <1% (N=17), 72.7% in patients with PD-L1 TPS of 1% to 49% (N=11), and 95.0% in patients with PD-L1 TPS ≥50% (N=20), respectively. The overall DCR was 97.9%. The median
More news about: D3 Bio
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
benefits."About IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein)IBI363 is a first-in-class PD-1/IL-2α-bias bispecific fusion protein developed by Innovent Biologics. It functions by both blocking the PD-1/PD-L1 pathway and selectively activating
More news about: Innovent Biologics